Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sleep latency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Sleep latency. Displaying page 5 of 5.
    « Previous 1  2  3  4  5 
    EudraCT Number: 2013-004884-30 Sponsor Protocol Number: P13-04/BP1.4979 Start Date*: 2017-12-07
    Sponsor Name:BIOPROJET PHARMA
    Full Title: Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).
    Medical condition: Restless Legs Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10058920 Restless legs syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001563-26 Sponsor Protocol Number: NCT05355337 Start Date*: 2022-10-03
    Sponsor Name:Region Skåne
    Full Title: Pramipexole for Anhedonic Depression (PRIME-PRAXOL)
    Medical condition: The effect of nine weeks of treatment with the dopamine agonist Pramipexole in patients with depression with clinically significant anhedonia will be evaluated with symptom rating scales, blood and...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10002511 Anhedonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001506-29 Sponsor Protocol Number: P11-06/BF2.649 Start Date*: 2016-06-14
    Sponsor Name:Bioprojet
    Full Title: DOUBLE BLIND, MULTICENTRE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE SAFETY AND EFFICACY OF PITOLISANT IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY WITH/WITHOUT CATAPLEXY, FOLLOW...
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028713 Narcolepsy PT
    20.0 10029205 - Nervous system disorders 10048322 Narcolepsy aggravated LLT
    20.0 10029205 - Nervous system disorders 10007737 Cataplexy PT
    20.0 10029205 - Nervous system disorders 10048323 Cataplexy aggravated LLT
    20.0 10029205 - Nervous system disorders 10028715 Narcolepsy with cataplexy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) FR (Trial now transitioned) DE (Prematurely Ended) NL (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004478-24 Sponsor Protocol Number: OV101-18-002 Start Date*: 2020-06-05
    Sponsor Name:Ovid Therapeutics Inc.
    Full Title: An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)
    Medical condition: Angelman Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049004 Angelman's syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001530-34 Sponsor Protocol Number: PPVMvhH/146-2011/MvhH Start Date*: 2012-08-09
    Sponsor Name:VU University Medical Center [...]
    1. VU University Medical Center
    2. Center Human Drug Research
    Full Title: Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study
    Medical condition: Idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004293-25 Sponsor Protocol Number: RD.06.SPR.202685 Start Date*: 2020-06-25
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) HU (Completed) AT (Completed) DK (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004789-17 Sponsor Protocol Number: RD.06.SPR.203065 Start Date*: 2020-07-08
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
    Medical condition: Prurigo Nodularis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10037084 Prurigo nodularis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001631-31 Sponsor Protocol Number: DHCL2019 Start Date*: 2019-07-10
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Dual-Hormone Closed-Loop Glucose Control in Type 1 Diabetes
    Medical condition: Patients with type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003008-11 Sponsor Protocol Number: JZP865-101 Start Date*: 2020-08-31
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects with Narcolepsy
    Medical condition: Narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10021235 Idiopathic narcolepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001389-93 Sponsor Protocol Number: 13-005 Start Date*: 2015-08-27
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Su...
    Medical condition: Narcolepsy with Cataplexy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10007738 Cataplexy and narcolepsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) NL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014544-11 Sponsor Protocol Number: C10953/3069/ES/MN Start Date*: 2010-05-21
    Sponsor Name:Cephalon Inc
    Full Title: Estudio abierto de 12 meses para la evaluación de la seguridad, la tolerabilidad y la eficacia de armodafinil (150 mg/día y 250 mg/día) como tratamiento para pacientes con somnolencia excesiva asoc...
    Medical condition: Pacientes con somnolencia excesiva asociada a un trauma craneo-cerebral no penetrante leve o moderado. Excessive sleepiness accociated with mild or moderate closed traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060690 Traumatic brain injury LLT
    12.0 10015595 Excessive daytime sleepiness LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 20:53:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA